J&J oncology vet takes the helm at foundering Dendreon

Struggling Dendreon ($DNDN) has named a new CEO in W. Thomas Amick, a longtime Johnson & Johnson ($JNJ) vet. There, he launched Procrit and built J&J's oncology franchise into a multibillion-dollar operation, Dendreon said Thursday. But he'll have his hands full with the Seattle-based biotech, which is facing dismal sales of its cancer vaccine, Provenge, and a debt pileup. Release

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.